Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

5.53
-1.1300-16.97%
Volume:14.89M
Turnover:87.52M
Market Cap:101.26M
PE:-0.31
High:6.50
Open:6.05
Low:5.42
Close:6.66
52wk High:10.99
52wk Low:3.51
Shares:18.31M
Float Shares:16.00M
Volume Ratio:48.21
T/O Rate:93.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9300
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-41.56%
PB:-0.35
PE(LYR):-0.31

Loading ...

Karyopharm Grants 1,450 RSUs to Newly Hired Employees Under Inducement Plan

Reuters
·
Mar 03

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Mar 03

Piper Sandler Reaffirms Their Buy Rating on Karyopharm Therapeutics (KPTI)

TIPRANKS
·
Feb 19

Karyopharm Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 18

Karyopharm Therapeutics Faces Rising Regulatory and Political Risks Amid Supreme Court Limits on FDA Authority

TIPRANKS
·
Feb 14

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Karyopharm Therapeutics (KPTI)

TIPRANKS
·
Feb 14

UPDATE: Karyopharm Therapeutics Q4 Adj. EPS $(2.23) Misses $(1.99) Estimate

Benzinga
·
Feb 12

Karyopharm Therapeutics Showcases Pipeline Advances and Upcoming Phase 3 Data in Cancer Therapies

Reuters
·
Feb 12

BRIEF-Karyopharm Reports Fourth Quarter And Full Year 2025 Financial Results And Highlights Recent Company Progress

Reuters
·
Feb 12

Karyopharm Q4 revenue rises on XPOVIO demand

Reuters
·
Feb 12

Karyopharm Therapeutics Q4 EPS $(5.71) Misses $(1.99) Estimate, Sales $34.079M Miss $35.112M Estimate

Benzinga
·
Feb 12

Karyopharm reports FY 2025 total revenue of USD 146.07 million

Reuters
·
Feb 12

BRIEF-Karyopharm Therapeutics Q4 Net Income USD -102.198 Million

Reuters
·
Feb 12

Karyopharm Therapeutics Q4 Operating Expenses USD 51.923 Million

THOMSON REUTERS
·
Feb 12

Karyopharm Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Feb 05

Karyopharm Therapeutics Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht

Reuters
·
Feb 05

Karyopharm initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Feb 05

BRIEF-Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Feb 03

Karyopharm Therapeutics Grants RSUs to New Employees Under Inducement Plan

Reuters
·
Feb 03

Kristin Abate, Chief Accounting Officer, Reports Sale of Karyopharm Therapeutics Inc. Common Shares

Reuters
·
Jan 23